1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
WooGene B&G Co., Ltd.

WooGene B&G Co., Ltd.

KKRX:018620
2,870.00
KRW
+145.00
(+5.32%)
-561.18EPS
19.99BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,814.3
6,391.29
6,741.65
6,474.55
5,850.16
6,229.39
5,517.39
6,224.14
5,662.56
6,215.93
8,357.89
8,042.92
7,848.29
7,896.85
Basic EPS, GAAP
201.1
237.68
101.17
46.87
-1,068.9
-1,516.91
-2,166.67
-325
-325
120.83
-170.83
-754.17
-254.17
-308.3
Free Cash Flow per Basic Share
-335.72
-260.77
-3,071.75
-3,120.44
-2,662.72
-1,071.79
-843.81
-499.32
236.08
302
-82.96
-225.38
151.74
187.1
Dividend per Share
- -
- -
54.89
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6,296.47
5,843.89
6,684.44
6,449.04
6,339.21
5,933.65
4,375.41
4,507.04
4,492.24
5,094.17
4,835.45
4,008.8
4,442.12
4,425.04
Tangible Book Value per Share
6,250.51
5,806.56
6,673.79
6,234.18
6,077.13
5,850.54
1,270.45
1,683.22
1,898.49
2,605.58
-308.65
517.09
1,185.2
1,226.79
Basic Weighted Avg Shares
3
3
3
4
4
4
6
6
7
7
7
7
7
7
Sales/Revenue/Turnover
20,546
22,087
23,507
24,235
22,934
27,236
32,559
39,524
39,347
43,703
57,919
55,680
54,764
54,748
Operating Margin (%)
3.74
3.86
- -
0.52
-14.89
-4.33
6.22
1.68
0.68
2.64
1.23
0.53
0.58
1.1
Depreciation Expense
754
864
867
882
1,496
2,551
2,640
2,143
2,229
2,312
3,955
3,922
4,183
4,213
Net Income, GAAP
606
821
353
175
-4,190
-6,632
-12,786
-2,064
-2,258
850
-1,184
-5,221
-1,774
-2,137
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
971.18
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
2.95
3.72
1.5
0.72
-18.27
-24.35
-39.27
-5.22
-5.74
1.94
-2.04
-9.38
-3.24
-3.9
Working Capital
5,242
6,978
10,486
8,232
-10,544
-4,897
16,056
2,946
8,780
21,683
4,113
8,958
5,897
7,810
LT Debt
72
1,500
11,850
23,163
11,200
10,400
7,923
5,328
4,931
5,140
4,348
6,404
8,747
9,785
Total Equity
18,991
20,672
21,904
22,138
23,039
26,513
38,703
42,010
44,564
64,566
72,330
69,415
63,936
63,827
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-31.95
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-34.73
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
3.23
4.14
1.66
0.8
-18.55
-26.77
-47.55
-7.23
-7.41
2.56
-3.44
-17.03
-6.05
-7.37

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
28,520
22,547
19,777
LT Borrowings
8,721
8,306
9,418
LT Finance Leases
518
441
367
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
26,894
24,005
19,990

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
44,063
35,196
34,429
Cash, Cash Equivalents & STI
24,379
15,568
12,328
Accounts Receivable, Net
7,993
7,592
8,925
Inventories
10,188
10,964
12,047
Total Current Liabilities
35,907
29,298
26,619
Payables & Accruals
- -
- -
- -
ST Debt
28,520
22,547
19,777
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.58%
10.21%
-7.89%
Free Cash Flow
-33.26%
-49.17%
-167.86%
Net Income, GAAP
-256.42%
-18.51%
-66.03%
Sales/Revenue/Turnover
9.5%
7.53%
-1.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16,068
14,428
11,690
13,494
55,680
2025
14,321
13,741
13,218
13,484
54,764
2026
14,305
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29.17
208.33
33.33
-1,025.33
-754.17
2025
50
217.46
-122.66
-399.67
-254.17
2026
-3.43
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Full Time Employees
103
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hwaseong-si South Korea
IPO Date
May 20, 2008
Website
woogenebng.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
WooGene B&G Co., Ltd. is a South Korea-based biotechnology and animal healthcare company that specializes in the research, development, manufacture, and commercialization of veterinary pharmaceuticals, animal biologicals, functional feed additives, companion animal nutrition, and eco-friendly microbial solutions. Founded in 1977 and headquartered in Seoul, South Korea, the company operates manufacturing and research facilities in Hwaseong and an advanced EU-GMP standard automated animal vaccine facility in Yesan. WooGene B&G operates through specialized business divisions offering an extensive commercial portfolio, which includes veterinary pharmaceuticals such as injectable antibiotics, anti-inflammatory therapeutics, anthelmintics, and water-soluble powders; veterinary biologicals and vaccines including the PED-M vaccine for Porcine Epidemic Diarrhea, the Immunis MegaVac series for aquatic iridovirus infections, lumpy skin disease vaccines, and autogenous herd-specific formulations; functional feed additives and probiotics consisting of microbial fermentation extracts, digestive enzyme complexes, and immune-enhancing feed supplements for swine, poultry, bovine, and aquaculture species; pet care products comprising premium organic and grain-free pet food through dedicated operating units, canine-derived postbiotic formulations, and Dr. Tummy brand nutritional supplements; and environmental bio-agents comprising biological odor removers, organic microbial fertilizers, and industrial wastewater treatment agents. The company distributes its products domestically and internationally across more than 25 countries throughout Southeast Asia, East Asia, and the Middle East, including Vietnam, Thailand, Malaysia, the Philippines, Japan, and the United Arab Emirates. In recent developments, WooGene B&G has expanded its commercial and strategic footprint through key supply contracts, including an export agreement with Vietnam's CP Group for specialized veterinary therapeutics, a multi-year supply agreement with South Korea's Public Procurement Service for supplementary feed products, and vaccine supply allocations for government lumpy skin disease prevention initiatives. To accelerate growth in the companion animal segment, the company completed a strategic equity investment in pet food manufacturer Bow Wow Korea and secured patents for antimicrobial postbiotic manufacturing technologies derived from canine probiotics. Additionally, WooGene B&G executed a five-to-one share consolidation in early 2026 to optimize its public share structure and enhance capital efficiency, alongside executive governance realignments and increased insider equity acquisitions.